Antisense Therapeutics Limited (ASX:ANP)
Share Pricing & News Healthcare

AUD 0.12

0.01 (9.091%)
(As on 2022-08-19 19:55:15 AEDT)
Previous Close Open Close*
0.11 0.135 0.12
Market Cap Dividend Yield (Annualized)
AUD 80.255M 0.00%

Day Range
0.115L 0.15 H
0.073L 0.3370602266 H

Chart Price & Information

Last Trade 0.12
Change% 9.0909
52 W H/L 0.337/0.073
EBITDA -9.531M
NPAT After Abnormal Items -8.061M
Equity 5.728M
ROE% -140.73%
Total Liabilities 1.273M
Total Revenue 632,654
Cash and Cash Equivalents 6.02M

Stock Information

Share price 0.12
Market Cap 80.255M
Price/Gross Cash Flow -20.24
Dividend Yield Excluding Special 0.00%
Ending Shares 574.476M
52-Week Range 0.337-0.073
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
P/E ratio 0.000
Sector P/E --
EPS -1.49
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.01
Net Gearing -99.76%
Sales Per Share 0.00
Book Value Per Share 0.01

Similar Companies

Related Articles

About Company

ASX-listed biopharmaceutical company Antisense Therapeutics Limited (ASX:ANP) that is engaged in the development and commercialisation of antisense pharmaceuticals for large unmet markets. The products of Antisense are in-licensed from Ionis Pharmaceuticals Inc, a world leader in antisense drug development and commercialisation. The drug pipeline of Antisense comprises two drug candidates- ATL1103 and ATL1102. Both these candidates are under clinical development, ATL1103 for the treatment of acromegaly and ATL1102 for multiple sclerosis and Duchenne Muscular Dystrophy (DMD).

Corporate Information

Level 1, 14 Wallace Avenue, TOORAK, VIC, AUSTRALIA, 3142

Phone:(03) 9827 8999



Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2023-02-22 2023
Report (Annual) 2022-10-28 2022
Report (Prelim) 2022-08-24 2022